Sile Li

Ms. Sile Li


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2021 in Cancers
Verified
Journal Article
Open access
PDF file
CXCHICHAO XIA
CHICHAO XIA
SLSile Li
Sile Li
TLTeng Long
Teng Long
ZCZigui Chen
Zigui Chen
CCChan Chan
Chan Chan
SBSiaw Shi Boon
Siaw Shi Boon
Human papillomavirus (HPV) infection remains one of the most prominent cancer-causing DNA viruses, contributing to approximately 5% of human cancers. While association between HPV and cervical cancers has been well-established, evidence on the attribution of head and neck cancers (HNC) to HPV have been increasing in recent years. Among the cancer-causing HPV genotypes, HPV16 and 18 remain the major contributors to cancers across the globe. Nonetheless, the distribution of HPV genotypes in ethnically, geographically, and socio-economically diverse East, Southeast, and South Asia may differ from other parts of the world. In this review, we garner and provide updated insight into various aspects of HPV reported in recent years (2015–2021) in these regions. We included: (i) the HPV genotypes detected in normal cancers of the uterine cervix and head and neck, as well as the distribution of the HPV genotypes by geography and age groups; (ii) the laboratory diagnostic methods and treatment regimens used within these regions; and (iii) the oncogenic properties of HPV prototypes and their variants contributing to carcinogenesis. More importantly, we also unveil the similarities and discrepancies between these aspects, the areas lacking study, and the challenges faced in HPV studies.

26 February 2026 in Advanced Science
Verified
Journal Article
Open access
PDF file
SLSile Li
Sile Li
YLYuanxin Li
Yuanxin Li
ARAsif Rashid
Asif Rashid
HTHong Kee Tan
Hong Kee Tan
SCShing Chan
Shing Chan
WLWing Leung
Wing Leung
The use of chimeric antigen receptor (CAR) T‐cell therapy for T‐cell malignancies is limited by fratricide, antigen‐escape, lack of functional endurance and adverse events such as multilineage cytopenia. To address these limitations, we developed a simple single‐step CD7‐depletion process followed by transduction with a lentiviral vector encoding a CCR4/CD7 bispecific CAR. CD7‐negative (CD7N) CCR4/CD7 CAR‐T cells could expand without experiencing fratricide, unlike the bulk CCR4/CD7 CAR‐T cells. The CD7N CAR‐T exhibited robust cytotoxicity against malignant T‐cell lines with heterogeneous CD7 and CCR4 expression in vitro and in vivo. Incorporation of EGFRt in the CAR construct allowed elimination by cetuximab in case of adverse events, whereas inclusion of c‐Jun in the construct reduced functional exhaustion after repeated tumor challenges in vitro. In comparison to non‐transduced CD7N cells and Bulk CAR‐T cells, scRNA‐seq analysis of CD7N CAR‐T cells revealed a unique AQP3+ CD4+ T‐cell subset following exposure to tumor cells. This cell subset exhibited broad activation of the Src/Ras/ERK and Bcl‐2 pathways, high levels of SOS1 and KLF2 expression, and specific ligand‐receptor interactions within the tumor necrosis factor superfamily. Collectively, these results suggest that further clinical development of CCR4/CD7 bispecific CD7N CAR‐T cells is warranted, including the AQP3+ subset with SOS1 / KLF2 modulation.